

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Keymed Biosciences Inc.
康諾亞生物醫藥科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2162)

VOLUNTARY ANNOUNCEMENT

CM310 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION BY THE CENTER FOR DRUG EVALUATION OF NMPA FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS

This announcement is made by Keymed Biosciences Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company is pleased to announce that the Center for Drug Evaluation of the National Medical Products Administration (the “**CDE**”) has granted CM310 recombinant humanized monoclonal antibody injection, a Class 1 innovative drug self-developed by the Group, breakthrough therapy designation for the treatment of moderate to severe atopic dermatitis. Phase III clinical trial is currently carried out in the PRC for this indication.

According to the announcement of the NMPA in relation to the publication of three documents including the Working Procedures for Review of Breakthrough Therapeutics (Trial) (No. 82 of 2020) (《國家藥監局關於發佈〈突破性治療藥物審評工作程序(試行)〉等三個文件的公告》(2020年第82號)), drugs that have been granted the breakthrough therapy designation are prioritized by the CDE in communications and exchange, and in receiving guidance to promote the drug development progress.

About CM310

CM310 recombinant humanized monoclonal antibody injection is an innovative humanized monoclonal antibody self-developed by Keymed Bioscience (Chengdu) Co., Ltd. (康諾亞生物醫藥科技(成都)有限公司), targeting human IL-4 receptor alpha subunit (IL-4R α). CM310 can selectively combine with IL-4R α to block out the combination of IL-4R α and IL-4 as well as IL-13, thus suppressing its bioactivity.

Cautionary Statement as required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop, market and/or commercialize CM310 successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board of Directors
Keymed Biosciences Inc.
Dr. Bo CHEN
Chairman

Hong Kong, June 15, 2022

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Bo CHEN, Dr. Changyu WANG and Dr. Gang XU as executive Directors; Mr. Qi CHEN, Dr. Min Chuan WANG and Mr. Yilun LIU as non-executive Directors; Prof. Xiao-Fan WANG, Prof. Yang KE, Mr. Cheuk Kin Stephen LAW and Prof. Linqing LIU as independent non-executive Directors.